Clinical Trial Update: Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A randomized Phase 2 trial evaluating axitinib with TRC105 versus axitinib alone in renal cell carcinoma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• TRC105 (carotuximab)

Snippet

Sponsor: Tracon Pharmaceuticals Inc. | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-10-19